In the Claims

- 1. (Previously amended) A multicomponent vaccine for ruminants comprising an immunogenically effective combination of a protective antigen component from at least six clostridial organisms, a protective antigen component from at least one non-clostridial organism and an adjuvant, wherein the vaccine is in a low dose volume of about 3 ml or less.
- 2. (Currently amended) A The multicomponent vaccine of claim 1 comprising an immunogenically effective combination of protective antigen components from at least seven clostridial organisms, a protective antigen component from at least one non-clostridial organism and an adjuvant, wherein the vaccine is in a low dose volume of about 3 ml or less.
- 3. (Previously amended) The vaccine according to Claim 1, wherein the clostridial organism is selected from the group consisting of Cl. chauvoei, Cl. septicum, Cl. novyi, Cl. perfringens type C, Cl perfringens type D, Cl. sordellii, Cl. haemolyticum and Cl. tetani.

-2-

Attorney Docket: I-95.184 US D1

- 4. (Previously amended) The vaccine according to Claim 1, wherein said non-clostridial organism is selected from the group consisting of a Gram negative bacterium, a Gram positive bacterium, a virus, a parasite and a rickettsia.
- (Previously amended) The vaccine according to Claim 4. wherein the non-clostridial organism is at least one Gram negative bacterium selected from the group consisting of B. somnus, M. bovis, P. haemolytica, P. multocida, E. coli, S. typhimurium, Leptospira spp. and C. foetus.
- 6. (Previously amended) The vaccine according to Claim 5, wherein the Gram negative bacterium is H. somnus.
- 7. (Previously amended) The vaccine according to Claim 5, wherein the Gram negative bacterium is M. bovis.
- 8. (Previously amended) The vaccine according to Claim 4, wherein the non-clostridial organism is at least one virus selected from the group consisting of infectious bovine rhinotracheitis virus, bovine viral diarrhea virus, parainfluenza type 3 virus, bovine respiratory syncytial virus and a combination of at least two thereof.
- 9. (Previously amended) The vaccine according to Claim 4, wherein the non-clostridial organism is at least one

-3-

Attorney Docket: I-95.184 US D1

parasite selected from the group consisting of Neospora spp., Tritrichimonas foctus and Cryptosporidium bovis.

10. (Canceled)

11. (Previously amended) The vaccine according to Claim 1, wherein the adjuvant is selected from the group consisting of a polymer, a block co-polymer, an oil-in-water emulsion, a water-in-oil emulsion, Al(OH)3, AlPO4, an extract of a bacterial cell wall, an extract of a plant, a liposome, a saponin and a combination of at least two thereof.

Claims 12-14 Cancelled

15. (Previously amended) The vaccine according to Claim 3, wherein the 6 clostridial organisms are selected from the group consisting of Cl. chauvoei, Cl. septicum, Cl. novyi, Cl. perfringens type C, Cl. perfringens type D, Cl. haemolyticum and Cl. sordellii.

16.(Cancelled)

17. (Previously amended) The vaccine according to Claim 2, wherein the 7 clostridial organisms are selected from the group consisting of Cl. chauvoci, Cl. septicum, Cl. novyi, Cl. perfringens type C, Cl. perfringens type D, Cl. sordellii, Cl. haemolyticum, and Cl. tetani.

Attorney Docket: I-95.184 US D1

1 : 13 : E 1 1

clostridial organism is from H. somnus.

19. (Previously amended) The vaccine according to claim 2, wherein the protective antigen component from 7 clostridial organisms is from Cl. chauvoei, Cl. septicum, Cl novyi, Cl. perfringens type C, Cl. perfringens, type D, Cl. haemolyticum and Cl. sordellii and the protective antigen component from a non-clostridial organism is from H. somnus.

20. (Canceled)

egya-gaa³ oo la 1920 kilometa Birille (EV INC).

- 21.(Canceled)
- 22. (Previously amended) The multicomponent vaccine for ruminants according to Claim 4, wherein at least one protective antigen component is from a virus.
- 23. (Presently amended) A The multicomponent vaccine for ruminants according to Claim 22, wherein the protective antigen component comprises a plurality of viruses.
- 24. (Previously amended) The vaccine according to Claim 23,

Attorney Docket: I-95.184 US D1

wherein the clostridial organisms are selected from the group consisting of Cl. chauvoei, Cl. septicum, Cl novyi, Cl. perfringens type C, Cl. perfringens, type D, Cl. sordellii, Cl. haemolyticum and Cl. tetani.

- 25. (Previously amended) The vaccine according to Claim 23, wherein the viruses are selected from the group consisting of infectious bovine rhinotracheitis, parainfluenza type 3 virus, bovine viral diarrhea virus and bovine respiratory syncytial virus.
- (Previously amended) The vaccine according to Claim 23, 26. wherein the adjuvant is sclected from the group consisting of a polymer, a block co-polymer, an oil-in-water emulsion, a water-in-oil emulsion, an extract of a plant and a combination of at least two thereof.

27. (Cancelled)

- 28'. (Previously amended) The vaccine according to Claim 2, wherein the non-clostridial organism is selected from the group consisting of a Gram negative bacterium, a Gram positive bacterium, a virus, a parasite and a rickettsia.
- 29. (Previously amended) The vaccinc according to Claim 28, wherein the non-clostridial organism is a Gram negative bacterium and said Gram negative bacterium is selected from

Attorney Docket: I-95.184 US D1 USSN: 10/748,524

the group consisting of H. somnus, M. bovis, P.haemolytica, P. multocida, E. coli, S. typhimurium, Leptospira spp. and C. foetus.

- 30. (Previously amended) The vaccine according to Claim 28, wherein the non-clostridial organism is a virus and the virus is selected from the group consisting of infectious bovine rhinotracheitis, parainfluenza type 3 virus, bovine viral diarrhea virus and bovinc respiratory syncytial virus.
- 31. (Previously amended) The vaccine according to Claim 28. wherein the non-clostridial organism is a parasite and the parasite is selected from the group consisting of Neospora spp., Tritrichimonas foetus and Cryptosporidia spp...

32. (Cancelled)

33. (Previously amended) The vaccine according to Claim 28, wherein the adjuvant is selected from the group consisting of a polymer, a block polymer, an oil-in-water emulsion, a water-in-oil emulsion, an extract of a plant, a liposome and a combination of at least two thereof.

Claims 34 - 39 (Cancelled)

40. (Previously amended) The vaccine according to claim 2, wherein the 7 clostridial organisms are C1. chauvoci, C1.

-7-

Attorney Docket: I-95.184 US D1 USSN: 10/748,524

septicum, Cl novyi, Cl. perfringens type C, Cl. perfringens type D, Cl. sordellii and Cl. haemolyticum and the protective antigen component from at least one non-clostridial organism is H. somnus or M. bovis.

- 41. (Previously amended) A multicomponent vaccine comprising a safe and immunogenically effective combination of a protective antigen component from 2 clostridial organisms which are selected from the group consisting of Cl. chauvoei, Cl. septicum, Cl novyi, Cl. perfringens type C, Cl. perfringens type D, Cl. sordellii, Cl. hacmolyticum and Cl. tetani; a protective antigen component from viruses selected from the group consisting of infectious bovine rhinotracheitis virus, parainfluenza type 3 virus, bovine viral diarrhea virus and bovine respiratory syncytial virus and an adjuvant, wherein the vaccine is in a dose size of 3.0 mL or less.
- 42. (Previously amended) A multicomponent vaccine comprising a safe and immunogenically effective combination of a protective antigen component from 6 clostridial organisms, which are Cl. chauvoei, Cl. septicum, Cl novyi, Cl. perfringens type C, Cl. perfringens type D and Cl. sordellii; a protective antigen component from 4 viruses, which are infectious bovine rhinotracheitis virus, parainfluenza type 3 virus, bovine viral diarrhea virus and

Attorney Docket: I-95.184 US D1 USSN: 10/748,524

4.i. . . .

Claims 43-45 (Cancelled)

- 46. (Previously added) A method of immunizing an animal comprising administering an effective amount of the vaccinc of Claim 1.
- (Previously added) A method of immunizing an animal 47. comprising administering an effective amount of the vaccine of Claim 2.

Attorney Docket: I-95.184 US D1